Patents by Inventor Seong Ho Koh

Seong Ho Koh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12171812
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. An inflammatory composition comprising the above mentioned peptides is also described. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: December 24, 2024
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 12168039
    Abstract: The present invention relates to a method of treating autoimmune disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: December 17, 2024
    Assignee: GemVax & KAEL CO., LTD.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 12156902
    Abstract: The present invention relates to a method of treating bone, joint, muscle, and connective tissue related inflammatory disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: December 3, 2024
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20240158768
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 16, 2024
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Bum Joon KIM, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Hwain JANG, Jung Soon HA
  • Publication number: 20240091320
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has an outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: August 9, 2023
    Publication date: March 21, 2024
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Patent number: 11905536
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: February 20, 2024
    Assignees: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Bum Joon Kim, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Hwain Jang, Jung Soon Ha
  • Publication number: 20240000902
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: August 9, 2023
    Publication date: January 4, 2024
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Patent number: 11857607
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: January 2, 2024
    Assignees: GemVax & Kael Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20230293644
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 21, 2023
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Patent number: 11622998
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. An inflammatory composition comprising the above mentioned peptides is also described. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means, Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 11, 2023
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20220339198
    Abstract: The present invention relates to a pharmaceutical composition for Alzheimer's treatment containing as an active ingredient of late-stage human mesenchymal stem cells induced into glia-like cells (ghMSCs). When the glia-like cells differentiated from the late-stage human mesenchymal stem cells were co-cultured with neural stem cells having toxicity induced by amyloid beta, effects of increasing the reduced viability and proliferative potential of the neural stem cells and reducing the increased cytotoxicity of the neural stem cells were verified. In addition, the expression of inflammasomes is reduced, and effects of improving long-term memory with respect to spatial perception ability and enhancing spatial cognitive ability in Alzheimer-induced mouse models were verified. Therefore, the pharmaceutical composition of the present invention can be advantageously used in Alzheimer's treatment.
    Type: Application
    Filed: August 24, 2020
    Publication date: October 27, 2022
    Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Mi-Sook Chang, Seong-Ho Koh
  • Publication number: 20220331407
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: June 8, 2022
    Publication date: October 20, 2022
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Publication number: 20220331368
    Abstract: The present invention relates to a pharmaceutical composition comprising glia-like cells differentiated from human mesenchymal stem cells as an active ingredient for treatment of stroke. Specifically, as a result of injecting the glia-like cells differentiated from human mesenchymal stem cells (ghMSCs) of the present invention to cerebral infarction-induced animal models, the infarct volume remarkably decreased by 50% or more and neural functions were remarkably improved, compared to a control group and a group treated with human mesenchymal stem cells (hMSCs), demonstrating that ischemic stroke (infarction) is treated by the Akt pathway of IGFBP-4 via IGF-1R. Thus, the differentiated glia-like cells of the present invention can be advantageously used as a cell therapy product for stroke.
    Type: Application
    Filed: August 24, 2020
    Publication date: October 20, 2022
    Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Mi-Sook Chang, Seong-Ho Koh
  • Patent number: 11369665
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: June 28, 2022
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20210388328
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: July 30, 2021
    Publication date: December 16, 2021
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Bum Joon KIM, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Hwain JANG, Jung Soon HA
  • Patent number: 11098294
    Abstract: The present invention relates to methods of treating or preventing inflammation with a peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101. According to the present invention, the peptide of SEQ ID NO: 101 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the method comprising administration of the peptide of this invention can be used in anti-inflammatory pharmaceutical or cosmetic applications, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: August 24, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Bum Joon Kim, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Hwain Jang, Jung Soon Ha
  • Publication number: 20210228690
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: October 26, 2020
    Publication date: July 29, 2021
    Applicant: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Patent number: 10960056
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: March 30, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20210085757
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Patent number: 10898540
    Abstract: The present specification relates to a composition containing a peptide having effects of increasing telomerase activity and extending a telomere, and more specifically, to a composition containing a telomerase-derived peptide, thereby being effective for preventing, alleviating and treating diseases, caused by a decrease in telomerase activity or a reduction in telomere length, and symptoms caused by cell aging or damage. According to one aspect to the present invention, the peptide increases telomerase activity and is effective for extending a telomere, and thus a method for treating diseases induced by an abnormal decrease in telomerase activity and by the length reduction or loss of a telomere and alleviating symptoms caused thereby can be provided.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: January 26, 2021
    Assignee: Gem Vax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyuyong Lee, Seong Ho Koh